Vaccine Technologies Market is predicted to reach USD 102.9 billion at a CAGR of 10.80% during the forecast period

Market Research Future (MRFR) has published on the “Global Vaccine technologies Market”.

Vaccine Technologies Market Highlights

The global vaccine technologies market is accounted to register a CAGR of 10.80% during the forecast period and is estimated to reach USD 102.9 Billion by 2032.

Globally, the market for vaccination technologies is expanding quickly due to the COVID-19 pandemic and growing emphasis on preventative healthcare. The need for effective immunisation, government initiatives, and substantial research and development all contribute to the market's expansion, which presents prospects for mRNA, vector-based, and protein-based vaccines, among other vaccine technologies.

Key Players:

MRFR recognizes the following companies as the key players in the global vaccine technologies market— GlaxoSmithKline plc. (Brentford, U.K.), Sanofi (Paris, France), Pfizer Inc.  (New York, U.S.), Merck & Co., Inc. (New Jersey, U.S.), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, U.S.), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, U.S.), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan).

Segment Analysis

The global vaccine technologies market has been segmented based route of administration, disease indication, age group, and distribution channel.

The globe vaccine technologies market is classified into recombinant/conjugate/subunit, inactivated, live attenuated, and toxoid. In 2022, the inactive category dominated the market. Inactivated vaccines are based on time-tested technology that has been in use for many years. They are generated by removing or inactivating the pathogen that causes the sickness.

On the basis of route of administration, the market is segmented into parenteral and oral. The Oral category generated the most income in 2022. Oral vaccinations can be given without the need for injections or skilled medical professionals.

Based on disease indication, the global vaccine technologies market has been segmented into viral diseases and bacterial diseases. The viral diseases segment dominated the market in 2022. Viral infections significantly harm people's health on a global scale. Many common diseases, including COVID-19, measles, mumps, rubella, hepatitis, and the flu, are caused mostly by viral infections.

Based on age group, the global vaccine technologies market has been segmented into pediatric and adults. The pediatric segment dominated the market in 2022. Vaccination is a crucial component of the worldwide government-run paediatric immunisation programmes.

Based on distribution channel, the global vaccine technologies market has been segmented into hospital & retail pharmacies, government suppliers and others. The hospital & retail pharmacies segment dominated the market in 2022. Most hospitals and retail pharmacies have a wide network of locations, which makes it simple for the general public to get in touch with them.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Vaccine Technologies Market Research Report

Regional Analysis

The global vaccine technologies market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe vaccine technologies market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The vaccine technologies market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World vaccine technologies market comprises of Middle East, Africa, and Latin America.

The North America Vaccine technologies Market dominated this market in 2022 (45.80%). Due to the major players' investments in various R&D initiatives and the launch of new products in the United States. In-depth research being carried out by pharmaceutical and biotechnology companies is also anticipated to support the growth of the North American vaccine market.

Moreover, the second-largest market share for vaccine technologies is held by Europe. In European countries, public health and preventive medicine are highly regarded. Governments in Europe have historically given immunisation programmes considerable attention, which has resulted in high vaccination rates in the corresponding populations. This commitment to immunisation fuels the demand for vaccination technology in the region.

Additionally, due to the increased prevalence of diseases, rising expenses, and expanding access to healthcare in developing countries like China and India, the Asia-Pacific Vaccine Technologies Market is anticipated to grow at the fastest CAGR from 2023 to 2032.

Furthermore, due to the urgent need for vaccination against diseases like COVID-19 and the region's growing emphasis on healthcare, the market for vaccine technologies in Latin America is expanding significantly. Governmental initiatives, growing healthcare spending, and partnerships with vaccine manufacturers all contribute to the market's expansion and provide doors for different vaccine technologies throughout Latin America.

Key Findings of the Study

• The global vaccine technologies market is expected to reach USD 102.9 Billion by 2032, at a CAGR of 10.80% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the expanding availability to healthcare in developing countries like China and India, the rising expenses of healthcare, and the increasing prevalence of diseases.


• Based on route of administration, the oral segment was attributed to holding the largest market in 2022


• GlaxoSmithKline plc. (Brentford, U.K.), Sanofi (Paris, France), Pfizer Inc. (New York, U.S.), Merck & Co., Inc. (New Jersey, U.S.), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, U.S.), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, U.S.), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan).